<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430248</url>
  </required_header>
  <id_info>
    <org_study_id>F-GT06-153</org_study_id>
    <secondary_id>U1111-1114-0226</secondary_id>
    <nct_id>NCT00430248</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Febuxostat in Participants With Gout</brief_title>
  <acronym>CONFIRMS</acronym>
  <official_title>A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily
      (QD), to allopurinol in subjects with hyperuricemia and gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal impairment is common in subjects with gout, with the prevalence ranging from 50% to
      70%. This population represents an unmet medical need as uricosuric drugs are contraindicated
      in these patients, and the only available treatment, allopurinol, may have to be dose reduced
      to avoid overt side effects.

      Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as
      an orally administered agent for management of hyperuricemia in patients with gout.

      Treatment duration will be 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level is &lt;6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.</measure>
    <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
    <description>The percentage of subjects whose serum urate level was &lt;6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is &lt;6.0 mg/dl</measure>
    <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
    <description>The percentage of subjects with mild-to-moderate renal impairment whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 2 Visit.</measure>
    <time_frame>Month 2</time_frame>
    <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 2 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 4 Visit.</measure>
    <time_frame>Month 4</time_frame>
    <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 4 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 6 Visit.</measure>
    <time_frame>Month 6</time_frame>
    <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 6 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 2 Visit.</measure>
    <time_frame>Month 2</time_frame>
    <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 2 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 4 Visit.</measure>
    <time_frame>Month 4</time_frame>
    <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 4 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 6 Visit.</measure>
    <time_frame>Month 6</time_frame>
    <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 6 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Final Visit.</measure>
    <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
    <description>The percentage of subjects whose serum urate level was &lt;5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 2 Visit</measure>
    <time_frame>Month 2</time_frame>
    <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 2 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 4 Visit</measure>
    <time_frame>Month 4</time_frame>
    <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 4 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 6 Visit</measure>
    <time_frame>Month 6</time_frame>
    <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 6 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Final Visit</measure>
    <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
    <description>The percentage of subjects whose serum urate level was &lt;4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.</measure>
    <time_frame>Baseline and Month 2</time_frame>
    <description>Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit</measure>
    <time_frame>Baseline and Month 4</time_frame>
    <description>Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.</measure>
    <time_frame>Baseline and Last Visit on treatment (up to 6 months)</time_frame>
    <description>The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2269</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol 200 mg or 300 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(dependent on renal function)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.</description>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.
Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.</description>
    <arm_group_label>Allopurinol 200 mg or 300 mg QD</arm_group_label>
    <other_name>Zyloprim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has one or more of the American Rheumatism Association criteria for the diagnosis of
             gout.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Must have a serum urate level greater than or equal to 8.0 milligram per deciliter
             (mg/dL).

        Exclusion Criteria:

          -  Have a severe, unstable, or life threatening medical condition that would likely
             prevent them from completing this study.

          -  Has a known body reaction to febuxostat, allopurinol, naproxen, any other
             non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or
             any components in their formulation.

          -  History of xanthinuria.

          -  Alcohol consumption greater than 14/week.

          -  History of significant concomitant illness.

          -  Active liver or peptic ulcer disease.

          -  Has rheumatoid arthritis requiring treatment.

          -  Has estimated creatinine clearance less than 30 milliliter per minute (mL/min)
             calculated using the Cockcroft-Gault formula corrected for ideal body weight.

          -  Requires therapy with any other urate-lowering drug other than the study drug;
             long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics;
             losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine;
             cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hueytown</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northport</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ozark</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sierra Vista</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clovis</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Highlands Ranch</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holly Hill</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opa Locka</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruston</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prince Frederick</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blackwood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manalapan</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midland Park</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austintown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hudson</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Norriton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Feasterville Trevose</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrisville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scotland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gig Harbor</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&amp;fileTypeCode=ULORICPI</url>
    <description>Uloric Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6.</citation>
    <PMID>20370912</PMID>
  </results_reference>
  <results_reference>
    <citation>Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.</citation>
    <PMID>21353107</PMID>
  </results_reference>
  <results_reference>
    <citation>Becker MA, MacDonald PA, Hunt B, Gunawardhana L. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1011-7. doi: 10.1080/15257770.2011.603715.</citation>
    <PMID>22132950</PMID>
  </results_reference>
  <results_reference>
    <citation>Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.</citation>
    <PMID>22052584</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <results_first_submitted>March 12, 2009</results_first_submitted>
  <results_first_submitted_qc>May 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tophi</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>uric acid</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 324 sites in the United States from 16 February 2007 to 12 March 2008.</recruitment_details>
      <pre_assignment_details>Subjects who were currently receiving urate-lowering therapy discontinued those urate-lowering therapies and initiated prophylactic medications before enrollemnt in once daily (QD) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Allopurinol 200 mg or 300 mg QD</title>
          <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="757"/>
                <participants group_id="P2" count="756"/>
                <participants group_id="P3" count="756"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="632"/>
                <participants group_id="P2" count="598"/>
                <participants group_id="P3" count="621"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapeutic Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gout Flare</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Allopurinol 200 mg or 300 mg QD</title>
          <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="757"/>
            <count group_id="B2" value="756"/>
            <count group_id="B3" value="756"/>
            <count group_id="B4" value="2269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to &lt;65 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="450"/>
                    <measurement group_id="B2" value="432"/>
                    <measurement group_id="B3" value="445"/>
                    <measurement group_id="B4" value="1327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="11.68"/>
                    <measurement group_id="B2" value="53.0" spread="11.79"/>
                    <measurement group_id="B3" value="52.9" spread="11.73"/>
                    <measurement group_id="B4" value="52.8" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="722"/>
                    <measurement group_id="B2" value="710"/>
                    <measurement group_id="B3" value="709"/>
                    <measurement group_id="B4" value="2141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="710"/>
                    <measurement group_id="B2" value="707"/>
                    <measurement group_id="B3" value="702"/>
                    <measurement group_id="B4" value="2119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="620"/>
                    <measurement group_id="B2" value="618"/>
                    <measurement group_id="B3" value="625"/>
                    <measurement group_id="B4" value="1863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18.5 kilograms per meter (kg/m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18.5 kg/m to &lt;25 kg/m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 kg/m to &lt;30 kg/m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="236"/>
                    <measurement group_id="B4" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 kg/m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="490"/>
                    <measurement group_id="B2" value="476"/>
                    <measurement group_id="B3" value="476"/>
                    <measurement group_id="B4" value="1442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Disease</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="320"/>
                    <measurement group_id="B4" value="972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="436"/>
                    <measurement group_id="B4" value="1297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Function</title>
          <description>Moderate renal impairment - baseline estimated creatinine clearance (CLcr) 30 milliliters per minute (mL/min) to 59 mL/min; Mild renal impairment - baseline estimated CLcr 60 mL/min to 89 mL/min; Normal renal function - estimated CLcr 90 mL/min.
CLcr calculated using the Cockroft-Gault formula corrected for ideal body weight.</description>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderate Renal Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Renal Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="365"/>
                    <measurement group_id="B4" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Renal Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="255"/>
                    <measurement group_id="B4" value="786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Body Mass Index</title>
          <units>kg/m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="6.37"/>
                    <measurement group_id="B2" value="32.9" spread="6.39"/>
                    <measurement group_id="B3" value="32.7" spread="6.23"/>
                    <measurement group_id="B4" value="32.8" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Urate</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="1.15"/>
                    <measurement group_id="B2" value="9.6" spread="1.20"/>
                    <measurement group_id="B3" value="9.5" spread="1.19"/>
                    <measurement group_id="B4" value="9.6" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level is &lt;6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.</title>
        <description>The percentage of subjects whose serum urate level was &lt;6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.</description>
        <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
        <population>Analysis was performed on intent-to-treat (ITT) subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate 8.0 mg/dL. A subject's baseline value was used in the primary analysis if no postbaseline serum urate level was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level is &lt;6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.</title>
          <description>The percentage of subjects whose serum urate level was &lt;6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.</description>
          <population>Analysis was performed on intent-to-treat (ITT) subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate 8.0 mg/dL. A subject's baseline value was used in the primary analysis if no postbaseline serum urate level was obtained.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="756"/>
                <count group_id="O3" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="67.1"/>
                    <measurement group_id="O3" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary comparison was between febuxostat 40 mg and allopurinol treatment groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of febuxostat 40 mg to allopurinol was declared if the value of the lower bound of the 95% confidence interval for the difference was greater than -10%.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <p_value_desc>The test for superiority was performed using Fisher's exact test (two-tailed 0.05 significance level).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparisons between treatment groups were performed using Fishers exact test (two-tailed 0.05 significance level).</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Difference in percentage</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.1</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparisons between treatment groups were performed using Fishers exact test (two-tailed 0.05 significance level).</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Difference in percentage</param_type>
            <param_value>21.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>17.0</ci_lower_limit>
            <ci_upper_limit>26.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is &lt;6.0 mg/dl</title>
        <description>The percentage of subjects with mild-to-moderate renal impairment whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
        <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
        <population>Analysis was performed on the ITT subjects with mild-to-moderate renal impairment (estimated creatinine clearance of 30 mL/min to 89 mL/min), with a post-baseline serum urate level.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is &lt;6.0 mg/dl</title>
          <description>The percentage of subjects with mild-to-moderate renal impairment whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
          <population>Analysis was performed on the ITT subjects with mild-to-moderate renal impairment (estimated creatinine clearance of 30 mL/min to 89 mL/min), with a post-baseline serum urate level.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="503"/>
                <count group_id="O3" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7"/>
                    <measurement group_id="O2" value="71.6"/>
                    <measurement group_id="O3" value="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 2 Visit.</title>
        <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 2 visit was summarized.</description>
        <time_frame>Month 2</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 2 Visit.</title>
          <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 2 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="691"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 4 Visit.</title>
        <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 4 visit was summarized.</description>
        <time_frame>Month 4</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 4 Visit.</title>
          <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 4 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="646"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="75.2"/>
                    <measurement group_id="O3" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 6 Visit.</title>
        <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 6 visit was summarized.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 6 Visit.</title>
          <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 6 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="596"/>
                <count group_id="O3" value="616"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="75.3"/>
                    <measurement group_id="O3" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.426</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 2 Visit.</title>
        <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 2 visit was summarized.</description>
        <time_frame>Month 2</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 2 Visit.</title>
          <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 2 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="691"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="45.9"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 4 Visit.</title>
        <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 4 visit was summarized.</description>
        <time_frame>Month 4</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 4 Visit.</title>
          <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 4 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="646"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="51.6"/>
                    <measurement group_id="O3" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.428</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 6 Visit.</title>
        <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 6 visit was summarized.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 6 Visit.</title>
          <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;5.0 mg/dL at the Month 6 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="596"/>
                <count group_id="O3" value="616"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                    <measurement group_id="O2" value="49.7"/>
                    <measurement group_id="O3" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Final Visit.</title>
        <description>The percentage of subjects whose serum urate level was &lt;5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.</description>
        <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
        <population>Analysis was performed on the ITT subjects with a post-baseline serum urate value.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Final Visit.</title>
          <description>The percentage of subjects whose serum urate level was &lt;5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.</description>
          <population>Analysis was performed on the ITT subjects with a post-baseline serum urate value.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="756"/>
                <count group_id="O3" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="44.0"/>
                    <measurement group_id="O3" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 2 Visit</title>
        <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 2 visit was summarized.</description>
        <time_frame>Month 2</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 2 Visit</title>
          <description>Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 2 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="691"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.421</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 4 Visit</title>
        <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 4 visit was summarized.</description>
        <time_frame>Month 4</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 4 Visit</title>
          <description>Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 4 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="646"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.520</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 6 Visit</title>
        <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 6 visit was summarized.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 6 Visit</title>
          <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;4.0 mg/dL at the Month 6 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="596"/>
                <count group_id="O3" value="616"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Final Visit</title>
        <description>The percentage of subjects whose serum urate level was &lt;4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.</description>
        <time_frame>Last Visit on treatment (up to 6 months)</time_frame>
        <population>Analysis was performed on the ITT subjects with a post-baseline serum urate value.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Final Visit</title>
          <description>The percentage of subjects whose serum urate level was &lt;4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.</description>
          <population>Analysis was performed on the ITT subjects with a post-baseline serum urate value.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="756"/>
                <count group_id="O3" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two-tailed).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.</title>
        <description>Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.</description>
        <time_frame>Baseline and Month 2</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.</title>
          <description>Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="691"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.1" spread="12.8"/>
                    <measurement group_id="O2" value="-44.5" spread="15.5"/>
                    <measurement group_id="O3" value="-33.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit</title>
        <description>Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.</description>
        <time_frame>Baseline and Month 4</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit</title>
          <description>Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="646"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.9" spread="13.1"/>
                    <measurement group_id="O2" value="-45.5" spread="15.6"/>
                    <measurement group_id="O3" value="-34.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.</title>
        <description>Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.</title>
          <description>Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="596"/>
                <count group_id="O3" value="616"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.6" spread="13.2"/>
                    <measurement group_id="O2" value="-45.1" spread="16.0"/>
                    <measurement group_id="O3" value="-34.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.</title>
        <description>The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
        <time_frame>Baseline and Last Visit on treatment (up to 6 months)</time_frame>
        <population>Analysis was performed on the ITT subjects with a post-baseline serum urate value.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 200 mg or 300 mg QD</title>
            <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.</title>
          <description>The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
          <population>Analysis was performed on the ITT subjects with a post-baseline serum urate value.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="756"/>
                <count group_id="O3" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="15.5"/>
                    <measurement group_id="O2" value="-40.6" spread="19.9"/>
                    <measurement group_id="O3" value="-31.3" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Allopurinol 200 mg or 300 mg QD</title>
          <description>Allopurinol, orally, for up to 6 months. Dose of allopurinol received was based on renal status. Subjects with normal renal function or mild renal impairment received 300 mg QD; subjects with moderate renal impairment received 200 mg QD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19"/>
                <counts group_id="E2" subjects_affected="28"/>
                <counts group_id="E3" subjects_affected="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytoses not elsewhere classified (NEC)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Thrombocytopenias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Conduction Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Cardiac Hypertensive Complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Heart Failures NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Ischaemic Coronary Artery Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner Ear Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute and Chronic Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Benign Neoplasms GastrointestinaI (Excluding Oral Cavity)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Dyspeptic Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Gastrointestinal &amp; Abdominal Pains (Excluding Oral and Throat)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcers and Perforation, Site Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Intestinal Ulcers and Perforation NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Gastrointestinal Haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Pain and Discomfort NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis and Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies to Food, Food Additives, Drugs and Other Chemicals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Anaphylactic Responses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal and Gastrointestinal Infections</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Bacterial Infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract and Lung Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Sepsis, Bacteraemia, Viraemia, and Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractures and Dislocations NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Muscle, Tendon and Ligament Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Procedural Complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Upper limb Fractures and Dislocations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Purine Metabolism Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Total Fluid Volume Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Related Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Joint Related Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Osteoarthropathies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Breast and Nipple Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Colonic Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Nervous System Neoplasms Unpecified Malignancy NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Nonsmall Cell Neoplasm Malignant/Respiratory Type Specified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Prostatic Neoplasms Benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Prostatic Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System Hemorrhages &amp; Cerebrovascular Accidents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Disturbances in Consciousness NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Increased Intracranial Pressure Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Neurological Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Transient Cerebrovascular Events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure and Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Renal Vascular and Ischaemic Conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic Signs, Symptoms and Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasms and Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
              <event>
                <sub_title>Pulmonary Thrombotic and Embolic Conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysms and Dissections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193"/>
                <counts group_id="E2" subjects_affected="167"/>
                <counts group_id="E3" subjects_affected="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea (Excluding Infective)</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infections</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver Function Analyses</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and Connective Tissues Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="757"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="756"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="756"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Sciences</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

